Global Gastrointestinal Stromal Tumors (GSTs) Treatment Supply, Demand and Key Producers, 2024-2030
Page: 119
Published Date: 26 Jan 2024
Category: Medical Care
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Gastrointestinal Stromal Tumors (GSTs) Treatment market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine.
This report studies the global Gastrointestinal Stromal Tumors (GSTs) Treatment demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Gastrointestinal Stromal Tumors (GSTs) Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gastrointestinal Stromal Tumors (GSTs) Treatment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Gastrointestinal Stromal Tumors (GSTs) Treatment total market, 2019-2030, (USD Million)
Global Gastrointestinal Stromal Tumors (GSTs) Treatment total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment total market, key domestic companies and share, (USD Million)
Global Gastrointestinal Stromal Tumors (GSTs) Treatment revenue by player and market share 2019-2024, (USD Million)
Global Gastrointestinal Stromal Tumors (GSTs) Treatment total market by Type, CAGR, 2019-2030, (USD Million)
Global Gastrointestinal Stromal Tumors (GSTs) Treatment total market by Application, CAGR, 2019-2030, (USD Million).
This reports profiles major players in the global Gastrointestinal Stromal Tumors (GSTs) Treatment market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Bayer, Novartis, Immunicum, Roche, AB Science, Arog Pharmaceuticals, Boston Biomedical and Sun Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gastrointestinal Stromal Tumors (GSTs) Treatment market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market, Segmentation by Type
Surgery
Targeted Therapy
Radiation Therapy
ChemOthersapy
Others
Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market, Segmentation by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Companies Profiled:
Pfizer
Bayer
Novartis
Immunicum
Roche
AB Science
Arog Pharmaceuticals
Boston Biomedical
Sun Pharmaceutical
Natco Pharma
Key Questions Answered
1. How big is the global Gastrointestinal Stromal Tumors (GSTs) Treatment market?
2. What is the demand of the global Gastrointestinal Stromal Tumors (GSTs) Treatment market?
3. What is the year over year growth of the global Gastrointestinal Stromal Tumors (GSTs) Treatment market?
4. What is the total value of the global Gastrointestinal Stromal Tumors (GSTs) Treatment market?
5. Who are the major players in the global Gastrointestinal Stromal Tumors (GSTs) Treatment market?
Table of Contents
1 Supply Summary
1.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
1.2 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size & Forecast (2019 & 2023 & 2030)
1.3 World Gastrointestinal Stromal Tumors (GSTs) Treatment Total Market by Region (by Headquarter Location)
1.3.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region (2019-2030), (by Headquarter Location)
1.3.2 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.3.3 China Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.3.4 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.3.5 Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.3.6 South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.3.7 ASEAN Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.3.8 India Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Major Market Trends
2.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.2 World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region
2.2.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2019-2024)
2.2.2 World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Forecast by Region (2025-2030)
2.3 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.4 China Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.5 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.6 Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.7 South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.8 ASEAN Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
2.9 India Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030)
3.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Player (2019-2024)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Gastrointestinal Stromal Tumors (GSTs) Treatment in 2023
3.2.3 Global Concentration Ratios (CR8) for Gastrointestinal Stromal Tumors (GSTs) Treatment in 2023
3.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Company Evaluation Quadrant
3.4 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Overall Company Footprint Analysis
3.4.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Region Footprint
3.4.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Type Footprint
3.4.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4.1 United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
4.1.2 United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share Comparison (2019 & 2023 & 2030)
4.2 United States Based Companies VS China Based Companies: Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Comparison
4.2.1 United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share Comparison (2019 & 2023 & 2030)
4.3 United States Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies and Market Share, 2019-2024
4.3.1 United States Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (2019-2024)
4.4 China Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue and Market Share, 2019-2024
4.4.1 China Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (2019-2024)
4.5 Rest of World Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies and Market Share, 2019-2024
4.5.1 Rest of World Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (2019-2024)
5.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Surgery
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.4 ChemOthersapy
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2019-2024)
5.3.2 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2025-2030)
5.3.3 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Market Share by Type (2019-2030)
6.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Ambulatory Surgical Centers
6.2.4 Others
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2019-2024)
6.3.2 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2025-2030)
6.3.3 World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2019-2030)
7.1 Pfizer
7.1.1 Pfizer Details
7.1.2 Pfizer Major Business
7.1.3 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.1.4 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.1.5 Pfizer Recent Developments/Updates
7.1.6 Pfizer Competitive Strengths & Weaknesses
7.2 Bayer
7.2.1 Bayer Details
7.2.2 Bayer Major Business
7.2.3 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.2.4 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.2.5 Bayer Recent Developments/Updates
7.2.6 Bayer Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.3.4 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Immunicum
7.4.1 Immunicum Details
7.4.2 Immunicum Major Business
7.4.3 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.4.4 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.4.5 Immunicum Recent Developments/Updates
7.4.6 Immunicum Competitive Strengths & Weaknesses
7.5 Roche
7.5.1 Roche Details
7.5.2 Roche Major Business
7.5.3 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.5.4 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.5.5 Roche Recent Developments/Updates
7.5.6 Roche Competitive Strengths & Weaknesses
7.6 AB Science
7.6.1 AB Science Details
7.6.2 AB Science Major Business
7.6.3 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.6.4 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.6.5 AB Science Recent Developments/Updates
7.6.6 AB Science Competitive Strengths & Weaknesses
7.7 Arog Pharmaceuticals
7.7.1 Arog Pharmaceuticals Details
7.7.2 Arog Pharmaceuticals Major Business
7.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.7.4 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.7.5 Arog Pharmaceuticals Recent Developments/Updates
7.7.6 Arog Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Boston Biomedical
7.8.1 Boston Biomedical Details
7.8.2 Boston Biomedical Major Business
7.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.8.4 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.8.5 Boston Biomedical Recent Developments/Updates
7.8.6 Boston Biomedical Competitive Strengths & Weaknesses
7.9 Sun Pharmaceutical
7.9.1 Sun Pharmaceutical Details
7.9.2 Sun Pharmaceutical Major Business
7.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.9.4 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.9.5 Sun Pharmaceutical Recent Developments/Updates
7.9.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
7.10 Natco Pharma
7.10.1 Natco Pharma Details
7.10.2 Natco Pharma Major Business
7.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
7.10.4 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024)
7.10.5 Natco Pharma Recent Developments/Updates
7.10.6 Natco Pharma Competitive Strengths & Weaknesses
8.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Industry Chain
8.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Upstream Analysis
8.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Midstream Analysis
8.4 Gastrointestinal Stromal Tumors (GSTs) Treatment Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
Table 2. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
Table 3. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
Table 4. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share by Region (2019-2024), (by Headquarter Location)
Table 5. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share by Region (2025-2030), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
Table 8. World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2019-2024) & (USD Million)
Table 9. World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Forecast by Region (2025-2030) & (USD Million)
Table 10. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Player (2019-2024) & (USD Million)
Table 11. Revenue Market Share of Key Gastrointestinal Stromal Tumors (GSTs) Treatment Players in 2023
Table 12. World Gastrointestinal Stromal Tumors (GSTs) Treatment Industry Rank of Major Player, Based on Revenue in 2023
Table 13. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Company Evaluation Quadrant
Table 14. Head Office of Key Gastrointestinal Stromal Tumors (GSTs) Treatment Player
Table 15. Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Type Footprint
Table 16. Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Application Footprint
Table 17. Gastrointestinal Stromal Tumors (GSTs) Treatment Mergers & Acquisitions Activity
Table 18. United States VS China Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 19. United States VS China Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 20. United States Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (2019-2024) & (USD Million)
Table 22. United States Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share (2019-2024)
Table 23. China Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (2019-2024) & (USD Million)
Table 25. China Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share (2019-2024)
Table 26. Rest of World Based Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (2019-2024) & (USD Million)
Table 28. Rest of World Based Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share (2019-2024)
Table 29. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type, (USD Million), 2019 & 2023 & 2030
Table 30. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2019-2024) & (USD Million)
Table 31. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2025-2030) & (USD Million)
Table 32. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application, (USD Million), 2019 & 2023 & 2030
Table 33. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2019-2024) & (USD Million)
Table 34. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2025-2030) & (USD Million)
Table 35. Pfizer Basic Information, Area Served and Competitors
Table 36. Pfizer Major Business
Table 37. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 38. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 39. Pfizer Recent Developments/Updates
Table 40. Pfizer Competitive Strengths & Weaknesses
Table 41. Bayer Basic Information, Area Served and Competitors
Table 42. Bayer Major Business
Table 43. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 44. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 45. Bayer Recent Developments/Updates
Table 46. Bayer Competitive Strengths & Weaknesses
Table 47. Novartis Basic Information, Area Served and Competitors
Table 48. Novartis Major Business
Table 49. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 50. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 51. Novartis Recent Developments/Updates
Table 52. Novartis Competitive Strengths & Weaknesses
Table 53. Immunicum Basic Information, Area Served and Competitors
Table 54. Immunicum Major Business
Table 55. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 56. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 57. Immunicum Recent Developments/Updates
Table 58. Immunicum Competitive Strengths & Weaknesses
Table 59. Roche Basic Information, Area Served and Competitors
Table 60. Roche Major Business
Table 61. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 62. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 63. Roche Recent Developments/Updates
Table 64. Roche Competitive Strengths & Weaknesses
Table 65. AB Science Basic Information, Area Served and Competitors
Table 66. AB Science Major Business
Table 67. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 68. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 69. AB Science Recent Developments/Updates
Table 70. AB Science Competitive Strengths & Weaknesses
Table 71. Arog Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Arog Pharmaceuticals Major Business
Table 73. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 74. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 75. Arog Pharmaceuticals Recent Developments/Updates
Table 76. Arog Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Boston Biomedical Basic Information, Area Served and Competitors
Table 78. Boston Biomedical Major Business
Table 79. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 80. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 81. Boston Biomedical Recent Developments/Updates
Table 82. Boston Biomedical Competitive Strengths & Weaknesses
Table 83. Sun Pharmaceutical Basic Information, Area Served and Competitors
Table 84. Sun Pharmaceutical Major Business
Table 85. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 86. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 87. Sun Pharmaceutical Recent Developments/Updates
Table 88. Natco Pharma Basic Information, Area Served and Competitors
Table 89. Natco Pharma Major Business
Table 90. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Services
Table 91. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 92. Global Key Players of Gastrointestinal Stromal Tumors (GSTs) Treatment Upstream (Raw Materials)
Table 93. Gastrointestinal Stromal Tumors (GSTs) Treatment Typical Customers
List of Figure
Figure 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Picture
Figure 2. World Gastrointestinal Stromal Tumors (GSTs) Treatment Total Market Size: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Gastrointestinal Stromal Tumors (GSTs) Treatment Total Market Size (2019-2030) & (USD Million)
Figure 4. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
Figure 5. World Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share by Region (2019-2030), (by Headquarter Location)
Figure 6. United States Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 7. China Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 8. Europe Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 9. Japan Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 10. South Korea Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 11. ASEAN Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 12. India Based Company Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (2019-2030) & (USD Million)
Figure 13. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 16. World Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region (2019-2030)
Figure 17. United States Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 18. China Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 20. Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 21. South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 22. ASEAN Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 23. India Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2019-2030) & (USD Million)
Figure 24. Producer Shipments of Gastrointestinal Stromal Tumors (GSTs) Treatment by Player Revenue ($MM) and Market Share (%): 2023
Figure 25. Global Four-firm Concentration Ratios (CR4) for Gastrointestinal Stromal Tumors (GSTs) Treatment Markets in 2023
Figure 26. Global Four-firm Concentration Ratios (CR8) for Gastrointestinal Stromal Tumors (GSTs) Treatment Markets in 2023
Figure 27. United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share Comparison (2019 & 2023 & 2030)
Figure 29. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type, (USD Million), 2019 & 2023 & 2030
Figure 30. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Market Share by Type in 2023
Figure 31. Surgery
Figure 32. Targeted Therapy
Figure 33. Radiation Therapy
Figure 34. ChemOthersapy
Figure 35. Others
Figure 36. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Market Share by Type (2019-2030)
Figure 37. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application, (USD Million), 2019 & 2023 & 2030
Figure 38. World Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Market Share by Application in 2023
Figure 39. Hospitals
Figure 40. Clinics
Figure 41. Ambulatory Surgical Centers
Figure 42. Others
Figure 43. Gastrointestinal Stromal Tumors (GSTs) Treatment Industrial Chain
Figure 44. Methodology
Figure 45. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Pfizer Bayer Novartis Immunicum Roche AB Science Arog Pharmaceuticals Boston Biomedical Sun Pharmaceutical Natco Pharma
Related Reports
15 Jan 2023
Medical Care
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
